Skip to main content
Premium Trial:

Request an Annual Quote

Eurogentec and Exiqon in Licensing Agreement

NEW YORK, March 19 -- Eurogentec of Sart-Tilman, Belgium, today announced a non-exclusive licensing agreement to manufacture and sell modified oligonucleotides produced with Exiqon's locked nucleic acid technology.

 

LNA is a proprietary nucleic acid analog, which is incorporated in synthetic DNA oligos to enhance sensitivity in genomics products. Eurogentec said in a statement that it plans to use the technology to develop new applications for expression profiling and real-time PCR. The products will be synthesized in Oswell, UK.

 

Exiqon is based in Copenhagen, Denmark.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.